563PUpdated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer. (23rd October 2018) - Yoshino, T; Iwata, H; Tamura, K; Takahashi, S; Redfern, C; Modi, S; Doi, T; Kawakami, H; Taniguchi, H; Takashima, A; Yamaguchi, K; Fisher, J; et al.